Plain-English translation of NCT06917950 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , an oral medication that helps the body produce more of its own red blood cells to treat anemia in people on kidney dialysis. Researchers want to see if this medication might also improve bone health and reduce depression and anxiety — problems that commonly affect dialysis patients. You'll be randomly assigned to either take or continue your current anemia treatment.
Most dialysis patients have severe anemia (low red blood cells), which makes them tired and increases health risks. While current treatments work, they don't always help everyone and can have side effects. This medication works differently and may offer additional benefits — researchers believe it might also help strengthen bones and improve mood, but these effects haven't been thoroughly studied in dialysis patients yet.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll be randomly placed in one of two groups: one taking the new medication three times per week by mouth, or one continuing your current anemia treatment. Both groups will have their blood checked regularly to measure hemoglobin levels and other markers of bone and mental health. You'll likely complete surveys about mood and anxiety, and may have additional tests to assess bone strength and nerve/muscle function over the study period.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Egypt